Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Array Technologies Q4 2025 Earnings Call - Record $2.2B Order Book and APA Integration Drive Momentum
Array closed 2025 with a clean, loud signal: revenue jumped 40% to nearly $1.3 billion, tracker volumes rose 35%, and the company finished the year with a record $2.2 billion order book. APA is now st...
- Revenue surged 40% in 2025 to nearly $1.3 billion, driven by 35% tracker volume growth and ASP increases tied to commodity price trends.
- Array exited 2025 with a record $2.2 billion order book and reported a 2x book-to-bill for both legacy Array and the newly acquired APA business.
- APA integration: APA contributed about $50 million to 2025 revenue, roughly $100 million to the order book, was immediately accretive to EBITDA in 2025, but slightly dilutive to gross margin that year.
- +11 more takeaways
The Trade Desk Q4 2025 Earnings Call - AI and Objectivity Position TTD to Capture Open Internet Spend
The Trade Desk closed 2025 with solid revenue and strong margins, even as footprinted weakness in CPG and auto held back growth. Q4 revenue was $847 million (14% year over year; 19% excluding politica...
- Q4 revenue was $847 million, up 14% year over year, and up approximately 19% when excluding political spend tied to the prior U.S. election.
- Full-year 2025 revenue reached $2.9 billion, a year-over-year increase of 18%, with platform spend of about $13.4 billion.
- Adjusted EBITDA for Q4 was roughly $400 million, about 47% of revenue; management expects full-year 2026 adjusted EBITDA margin to be approximately in line with 2025.
- +14 more takeaways
NVIDIA Q4 FY2026 Earnings Call - Agentic AI inflection drives record data center revenue and extended supply commitments into 2027
NVIDIA reported an astronomical Q4 with total revenue of $68 billion, up 73% year over year, led by a $62 billion data center quarter and a full-year data center haul of $194 billion, up 68% year over...
- Record quarter: total revenue $68 billion, up 73% year over year; Q4 data center revenue $62 billion, up 75% year over year and +22% sequentially.
- Full-year data center revenue reached $194 billion, up 68% year over year, and the data center business has scaled roughly 13x since fiscal 2023 (ChatGPT emergence).
- Management sees an agentic AI inflection: inference workloads are monetizing tokens, and the company argues "compute equals revenues" for customers, driving urgent CapEx demand.
- +17 more takeaways
Teladoc Health Q4 2025 Earnings Call - Insurance-fueled BetterHelp ramp and AI investments aim to counter subscription-to-visit drag
Teladoc closed 2025 with stable adjusted EBITDA but a top-line that still feels the aftershocks of a structural shift from subscription revenue to visit-based economics. Management reported consolidat...
- Consolidated Q4 2025 revenue was $642 million, slightly above prior year quarter; Q4 adjusted EBITDA was $84 million, a 13% margin.
- Full year 2025 consolidated revenue was $2.53 billion, down 1.5% year-over-year; full year adjusted EBITDA was $281 million, an 11.1% margin.
- Net loss per share for 2025 was $1.14, including notable non-cash/pre-tax items: $1.99 of amortization, $0.46 stock-based comp, $0.41 goodwill impairment, and $0.11 restructuring; discrete tax benefits partially offset these.
- +16 more takeaways
TKO Group Holdings Q4 2025 Earnings Call - Media rights and FIPs set up step-change to near 40% Adjusted EBITDA margin in 2026
TKO spent 2025 stitching together a playbook: blockbuster media rights, aggressive partnership wins, and a strategy to monetize location subsidies, all of which produce a sharp financial inflection in...
- Media rights are the engine: UFC secured a $7.7 billion deal with Paramount, WWE signed a $1.6 billion deal with ESPN for PLEs, and TKO now has over $15 billion of long-term media rights across UFC, WWE, PBR, and Zuffa Boxing.
- 2026 guidance is a step function: management targets $5.675 billion to $5.775 billion of revenue and $2.24 billion to $2.29 billion of Adjusted EBITDA, implying roughly 21% revenue growth and 43% Adjusted EBITDA growth year over year.
- Margin expansion is explicit and large, management guiding to approximately 39.6% Adjusted EBITDA margin at the midpoint, up about 600 basis points from 2025.
- +16 more takeaways
StandardAero Q4 2025 Earnings Call - LEAP Ramp and Cash Conversion Power Record Year
StandardAero closed 2025 with clear momentum, driven by a rapid LEAP industrialization, robust organic growth across core engine platforms, and a material swing into positive cash generation. Revenue ...
- 2025 was a record year, with total company revenue up 15.8% year over year and Adjusted EBITDA up 17% to $808 million.
- Free cash flow turned positive at $209 million for full-year 2025, with a $308 million quarterly improvement in Q4 driven by delivering engines held up by parts; management reported over $300 million of FCF generated in H2 2025.
- LEAP program ramped materially: 60 LEAP engines inducted in 2025 versus 10 in 2024, with second half 2025 LEAP revenues approximately 2.5 times first half revenues; company has developed more than 475 LEAP component repairs and completed its first full overhaul on the platform.
- +13 more takeaways
Sarepta Therapeutics Fourth Quarter 2025 Earnings Call - ELEVIDYS reset year as company guides $1.2B-$1.4B and CEO to retire
Sarepta entered 2026 with a strengthened balance sheet and a clear, if cautious, roadmap: $954 million in cash, a plan to be non-GAAP profitable and cash flow positive this year, and guidance of $1.2 ...
- Company finished 2025 with $954 million in cash and investments, up $89 million in Q4, and expects to be cash flow positive and non-GAAP profitable in 2026 while continuing pipeline investment.
- Sarepta provided full-year net product revenue guidance for 2026 of $1.2 billion to $1.4 billion for its approved therapies, recommending modelers bias toward the low end given ELEVIDYS timing uncertainty.
- Management labeled 2026 a critical reset year for ELEVIDYS, citing an information deficit after 2025 safety events, and is deploying enhanced educational programs and expanded field teams to rebuild demand.
- +12 more takeaways
Chime Q4 2025 Earnings Call - Chime Core Migration and MyPay Reset Drive Margin Acceleration and 2026 Profit Guidance
Chime closed 2025 with stronger-than-expected results, finishing Q4 with accelerating revenue, margin expansion and the full deployment of its homegrown ledger, Chime Core. Management says Chime Core ...
- Q4 2025 results beat guidance, capping a 2025 year with 31% revenue growth, and Q4 revenue growth of 25% year-over-year.
- Chime completed its multi-year migration to Chime Core, now 100% on its own transaction processor and ledger, which management says reduces transaction processing costs by ~60% and lowers cost to serve to roughly one-third of large banks and one-fifth of regional banks.
- Q4 transaction margin rose to 72% (from 69% in Q3) and management says Chime Core’s final stage delivered a 200 basis point gross margin benefit, supporting a long-term gross margin target of 90%.
- +13 more takeaways
Tucows Q4 2025 Earnings Call - Ting divestiture ongoing, Wavelo EBITDA guided lower on conservative Ting scenarios
Tucows fielded three investor questions emphasizing that the Ting divestiture process is active and not delayed by recent market volatility. Management says timelines are driven by asset specifics and...
- The company answered three investor questions following its Q4 2025 results.
- Ting divestiture process is ongoing, management says it has not been delayed by recent market volatility.
- Management believes external market volatility does not directly impact the Ting timeline; timelines are driven by asset specifics and diligence.
- +10 more takeaways
Maravai LifeSciences Q4 2025 Earnings Call - Restructuring Pays Off, Guiding to EBITDA Positive 2026 on ~$200M Revenue
Maravai closed 2025 with clear evidence the reset is working. Q4 marked the company’s first positive adjusted EBITDA in four quarters, driven by more than $65 million in annualized cost savings, stron...
- Company renamed reporting segments to TriLink (formerly Nucleic Acid Production) and Cygnus (formerly Biologic Safety Testing); nomenclature only, no change in segment composition.
- Full-year 2025 revenue was $185.7 million, beating guidance by about $0.7 million. Q4 revenue was $49.9 million, and excluding $14.3 million of high-volume COVID CleanCap sales in Q4 2024, Q4 revenue grew 18% year-over-year.
- TriLink generated $34.6 million of Q4 revenue, down 17% YoY, but excluding the COVID CleanCap comp, TriLink base revenue grew 25% YoY. TriLink full-year revenue was $119.8 million with adjusted EBITDA of negative $23.1 million.
- +16 more takeaways